Physician profile
Hernando Orjuela
NPI 1295732253
$2,972.63
in general payments reported to CMS, 2019-2025
19 companies · $358 in 2025
The $358 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $995 · 2020: $305 · 2021: $187 · 2022: $226 · 2023: $169 · 2024: $732 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,259.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $787.73 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $481.65 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.95 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $236.96 | 2023-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $198.84 | 2019-2023 | |
| Amarin Pharma, INC. | $186.29 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $123.41 | 2024 | Lifevest |
| Pfizer INC. | $104.96 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $101.83 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $88.15 | 2024-2025 | Eliquis, Camzyos |
| Philips North America LLC | $74.55 | 2024-2025 | Extended Holter, (Ck7) Extended Holter |
| Actelion Pharmaceuticals US, INC. | $58.55 | 2024-2025 | Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $43.90 | 2024-2025 | Livtencity |
| Abiomed | $28.49 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $25.42 | 2023-2024 | Inpefa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $20.82 | 2024 | |
| Bridgebio Pharma, INC. | $20.46 | 2025 | Attruby |
| Scpharmaceuticals INC. | $17.42 | 2025 | |
| Gilead Sciences, INC. | $15.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hernando Orjuela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.